Expression and clinical significance of survivin in ovarian cancer: A meta-analysis

Xiaoyan He1*, Kehu Yang2,3*, Hailin Wang1, Xiaohong Chen1, Huifang Wu1, Liang Yao2,3, Shouye Ma1*

1 Obstetrics and Gynecology Department, Gansu Provincial Hospital, Lanzhou, Gansu, China, 2 The Institute of Clinical Study and Evidence Based Medicine, Gansu Provincial Hospital, Lanzhou, Gansu, China, 3 Evidence-Based Medicine Center and Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, College of Basic Medicine, Lanzhou University, Lanzhou, Gansu, China

* These authors contributed equally to this work.

Abstract

To assess the clinicopathological significance of survivin in ovarian carcinoma through this meta-analysis. PubMed, EMBASE, Web of Science, and The Cochrane Library databases were searched for relevant studies published through September, 2017. Included studies reported the case-control study of surviving expression with ovarian cancer and its clinicopathological characteristics. The quality assessment was performed according to the Newcastle–Ottawa Scale (NOS) for quality assessment of case–control studies. Statistical analysis was performed with the software Stata 12.0. Twelve eligible studies with a total of 1097 patients were included in this meta-analysis. Survivin overexpression was closely related to FIGO stage (I-II vs. III-IV) of ovarian carcinoma (odds ratio [OR] = 0.26, 95% confidence interval [CI]: 0.16, 0.42), P < 0.00001), tumor grade (G1-G2 vs. G3) (OR = 0.29, 95% CI (0.17, 0.51), P < 0.0001), but was not significantly associated with lymphatic metastasis (OR = 1.53, 95%CI(0.77, 3.03, P = 0.23), ascites (OR = 0.89, 95%CI(0.39,2.05), P = 0.79).

Our meta-analysis shows that survivin is strongly associated with FIGO stage and tumor grade of ovarian carcinoma. Maybe survivin is a novel clinicopathological marker of ovarian carcinoma.

Introduction

Presently, ovarian cancer still remains the most fatal cancer of the female reproductive tract [1] due to vague symptomatology and the absence of reliable screening tests in the early stages [2]. The majority of these patients are diagnosed when treatment options are limited, and the overall 5-year survival rates do not exceed 30% [3]. Survivin is a member of the inhibitors of the apoptosis protein (IAP) family, and undetectable in normal adult tissues but highly expressed in several types of cancer, with a potential involvement in malignant transformation and tumor growth [4, 5]. High expression levels of this antiapoptotic protein have been previously found and shown to predict poorer prognosis and shorter survival in a wide range of human cancers, including the gastrocolic carcinoma [6, 7], breast cancer [8], lung [9], and ovary cancer [10, 11]. Thus, survivin is considered a novel clinicopathological marker for
numerous human malignant tumors and may be an important prognostic marker in cancer. However, the clinicopathological features associated with survivin expression in ovarian carcinoma remain controversial. To more precisely evaluate the relationship between surviving expression and clinicopathological outcome in ovarian carcinoma, we conducted a meta-analysis of 12 published studies.

Methods

Search strategy

We systematically searched PubMed, EMBASE, Web of Science, and The Cochrane Library databases for studies in humans on survivin expression with ovarian cancer and its clinicopathological characteristics, which were published from inception to September, 2017. Computer searches used combinations of subject headings or other key words by the following search strategy: (Ovarian tumor OR Ovarian cancer OR Ovarian carcinoma OR Ovarian malignancy OR Ovarian Neoplasms) AND (Survivin). PubMed database was searched as following: #1 Ovarian tumor[Title/Abstract] OR Ovarian cancer[Title/Abstract] OR Ovarian carcinoma[Title/Abstract] OR Ovarian malignancy[Title/Abstract] OR Ovarian Neoplasms[Title/Abstract] #2 "Ovarian Neoplasms"[Mesh] #3 #1 OR #2 #4 Survivin [Title/Abstract] #5 "Survivin"[Mesh] #6 #4 OR #5 #7 #3 AND #6.

Study selection

Included studies must meet the following criteria: (1) case-control study focus on the association between the survivin expression and ovarian cancer and its clinicopathological variables; (2) immunohistochemistry (IHC) or real-time PCR (RT-PCR) analysis to evaluate survivin expression in ovarian carcinoma; (3) None of the patients received radiotherapy, chemotherapy or tumor drug treatment before surgery; (4) All cases were not limited with race, nationality or age. The following studies were excluded: (1) conference abstracts, letters, reviews, case reports, commentaries, or expert opinions; (2) studies with insufficient information on clinicopathological characteristics.

Quality assessment

Study quality was independently assessed by two investigators according to the Newcastle-Ottawa Scale (NOS) for quality assessment of case–control studies [12]. The criteria were quality of selection, comparability, exposure and outcome; the scales allocate stars, with a maximum of nine. The study was evaluated as low quality when the score \( \leq 5 \) and excluded from our study, by contrast, the study was evaluated as high quality when the score was \( \geq 6 \) and included in our meta-analysis.

Data extraction

Two investigators independently extracted data that met our inclusion and exclusion criteria. Any discrepancies were resolved by consensus. We extracted the following information: name of the first author, year of publication, country, specific outcomes, total number of individuals, number of cases and controls, clinicopathological characteristics.

Statistical analysis

Pooled estimates of ORs with 95% CIs were used to evaluate the associations between survivin expression and clinicopathological characteristics of ovarian cancer. Heterogeneity among studies was evaluated with the Cochran Q test and \( I^2 \) statistic [13], inter-study heterogeneity...
was assumed in cases in which $I^2 > 50\%$, and ORs were pooled according to random-effects models. Alternatively, fixed-effects models were used. Sensitivity analyses evaluated whether the results could have been affected markedly by a single study [14]. In addition, Begg’s funnel plots and Egger’s test were used to statistically assess publication bias, there existed publication bias when p-value less than 0.05 [15]. We used STATA version 12.0 for all statistical analyses and to produce the forest plot. A p-value less than .05 was considered statistically significant.
Results

The initial search in the electronic databases identified 1195 articles. After excluding duplicate citations and studies that did not meet the inclusion criteria, twelve publications [11, 16–26] were finally included in the meta-analysis (Fig 1). A description of the baseline characteristics are summarized in Table 1. The analysis included 566 ovarian carcinoma cases. Study quality scores (range, 0–9) averaged 7.0, with a proportion of high-quality studies (quality score C8) of 33.3%.

Ovarian carcinoma vs normal ovarian tissues

A total of six studies [18, 22–26] reported the survivin expression in ovarian cancer vs normal ovarian tissues, with 314 cases of ovarian cancer patients and 79 normal women. There was no significant heterogeneity between the two groups (P = 0.95, I² = 0.0%), so fixed-effects models was used to analysis (Fig 2). Results show that the survivin expression in ovarian cancer is higher than normal group, the difference was statistically significant (OR = 72.14, 95% CI (21.70, 21.70), P < 0.00001).

Ovarian carcinoma vs ovarian benign tumor

A total of eleven studies [11, 16–23, 25, 26] reported the survivin expression in ovarian cancer vs ovarian benign tumor, with 528 cases of ovarian cancer patients and 262 ovarian benign.

Table 1. Characteristics and results of the included studies.

| Study   | Country   | No. of P. (1097) | Method | FIGOS Stage (I-II/III-IV) | tumor grade(G1/G2/G3) | lymph nodly metastasis(yes/no) | Survivin(+) | NOS |
|---------|-----------|-----------------|--------|--------------------------|-----------------------|--------------------------------|--------------|-----|
| Su[11]2002 | Japan     | 103             | IHC    | 19/28                    | 21/13/13              | 24/19                         | 24           | 11  | 7   |
| Ju[16]2016 | China     | 60              | IHC    | 19/20                    | 8/31*                 |                                | 8            | 3   | 1   |
| Kanter[17]2016 | Turkey     | 98             | IHC    |                          |                       |                                | 37           | 4   | 3   |
| Plewka[18]2015 | Europe     | 157           | IHC    |                          |                       |                                | 41           | 22  | 13  | 0   | 6   |
| Turan[19]2014 | Turkey     | 62              | IHC    |                          |                       |                                | 21           | 10  | 6   | 8   |
| Qian[20]2011 | China      | 91              | IHC    |                          |                       |                                | 55           | 4   | 0   | 7   |
| Huang[21]2011 | China      | 65              | IHC    | 7/18                     | 2/23*                 |                                | 26           | 6   | 5   | 8   |
| Liguang[22]2007 | China      | 114            | RT-PCR | 28/35                    | 30A/33                | 34/29                         | 46           | 9   | 4   | 0   | 6   |
| Gao[23]2007 | China      | 70              | IHC    | 10/36                    | 22A/24                |                                | 28           | 5   | 0   | 7   |
| Yin[24]2006 | China      | 69              | IHC    | 10/28                    | 13A/25                | 18/13                         | 29           | 9   | 0   | 7   |
| Ma[25]2006 | China      | 143             | IHC    | 41/43                    | 32/34/18              |                                | 53           | 12  | 0   | 7   |
| Zhang[26]2003 | China      | 65              | RT-PCR | 14/21                    | 24A/11                | 13/22                         | 29           | 8   | 2   | 0   | 6   |

*, G2-G3
Δ, G1-G2
No. of P, number of patients; NOS, Newcastle-Ottawa quality assessment scale; RT-PCR, reverse transcription polymerase chain reaction; IHC, immunohistochemistry

https://doi.org/10.1371/journal.pone.0194463.t001
tumor patients. There was heterogeneity between the two groups ($P = 0.004, I^2 = 61.2\%$), so random-effects models was used to analysis (Fig 3). Results show that the surviving expression in ovarian cancer is higher than ovarian benign tumor, the difference was statistically significant (OR = 9.86, 95%CI(5.13,18.95), $P < 0.00001$).

### Ovarian carcinoma vs borderline ovarian tumor

A total of ten studies [11, 16–22, 24, 26] reported the survivin expression in ovarian cancer vs borderline ovarian tumor, with 436 cases of ovarian cancer patients and 190 ovarian borderline tumor patients. There was heterogeneity between the two groups ($P = 0.0000, I^2 = 69.9\%$), so random-effects models was used to analysis (Fig 4). Results show that the surviving expression in ovarian cancer is higher than borderline ovarian tumor, the difference was statistically significant (OR = 3.65, 95%CI(1.73,7.69), $P = 0.000$).

### Survivin expression with clinicopathological characteristics

Survivin expression with FIGO stage A total of eight studies [11, 16, 21–26] reported the surviving expression in different FIGO stage of ovarian cancer, with 148 cases of I-II and cases of III- IV. There was no significant heterogeneity between the two groups ($P = 0.884, I^2 = 0\%$), so fixed-effects models was used to analysis (Fig 5). Results show that the surviving Expression in I-II is higher than III- IV, the difference was statistically significant (OR = 0.26, 95%CI (0.16,0.42), $P<0.00001$).
Survivin expression with tumor grade

A total of six studies [11, 22–26] reported the survivin expression in different tumor grade of ovarian cancer, with 189 cases of G1-G2 and 124 cases of G3. There was no significant heterogeneity between the two groups (\(P = 0.112, I^2 = 44\%\)), so fixed-effects models was used to analysis (Fig 6). Results show that the survivin expression in G1-G2 is lower than G3, the difference was statistically significant (OR = 0.29, 95%CI(0.17,0.51), \(P < 0.0001\)).

Survivin expression with lymphatic metastasis

A total of four studies [11, 22, 24, 26] reported the survivin expression in lymphatic metastasis of ovarian cancer, with 89 cases of metastasis and 83 cases of non-metastasis. There was no significant heterogeneity between the two groups (\(P = 0.133, I^2 = 46.4\%\)), so fixed-effects models was used to analysis (Fig 7). Results show that survivin expression was not significantly associated with lymphatic metastasis (OR = 1.53, 95%CI(0.77, 3.03, \(P = 0.23\)).

Sensitivity analysis

A sensitivity analysis omitting one study at a time and calculating the pooled ORs for the remainder of the studies in ovarian cancer vs ovarian benign tumor showed that the studies
by Kanter et al.[17], Qian et al. [20] and Ma et al.[25] substantially influenced the pooled risk estimates. By excluding these three studies, heterogeneity decreased dramatically ($I^2 = 33.4\%$; Table 2). In ovarian carcinoma vs borderline ovarian tumor, the studies by JU et al.[16], Kanter et al. [17], Qian et al.[20] and Sui et al. [11] substantially influenced the pooled risk estimates. By excluding these four studies, heterogeneity decreased dramatically ($I^2 = 0\%$; Table 2).

**Publication bias**

Begg’s funnel plots and Egger’s test were used to assess publication bias in the meta-analysis. There was no indication for publication bias in the Egger’s test of ovarian carcinoma vs ovarian benign tumor ($P = 0.073$) and ovarian carcinoma vs borderline ovarian tumor ($P = 1.000$) (Fig 8A and 8B).

**Discussion**

Ovarian cancer is one of the most common female cancers and the most frequent cause of gynecologic cancer-related deaths in the world. Hence, presence of biomarkers for the diagnosis, treatment and prediction of prognosis of ovarian neoplasms might guide the management of these patients. Survivin overexpression was found to be related with the aggressiveness of the tumor[27]. The use of survivin expression as a clinicopathological marker of malignancy
has received increasing attention. Over expression of survivin has been observed in esophageal, gastric, lung and cervical cancer tissues and represents a poor prognostic factor in these cancer patients [28–32]. Inhibition of apoptosis by survivin is associated with the mitotic spindle assembly checkpoint [33, 34]. Thus, survivin may be a potential target in the treatment of epithelial ovarian cancers. However, despite presence of many studies, definitive role of survivin in the progress of ovarian cancer remains unknown [10, 11, 20, 35] In this study, we investigated the expression and clinical significance of survivin in ovarian cancer in order to find the relationship between them. We found that survivin expression was positively correlated with the FIGO stage and tumor grade. These findings may implicate that survivin has a possible role in malignant potential of ovarian neoplasms. The results of quality evaluation of included studies in our meta-analysis showed that the average of NOS score was 7, and no study was evaluated less than 5, which illustrated that the quality of included studies in our meta-analysis were high. Our meta-analysis results indicate that, survivin expression in the ovarian cancer group is significantly higher than in the normal tissues and benign ovarian tumors (the OR value are as high as 72.14 and 9.86 respectively), with significant difference (P < 0.00001). In normal ovarian tissues and benign ovarian tumor could hardly detect survivin, indicate that survivin has not been activated, survivin was not involved in apoptosis regulation of normal ovarian cells and benign ovarian tissues. However, survivin expressed in ovarian cancer stably, abnormal expression of survivin may result in the occurrence of ovarian cancer by inhibiting apoptosis. Survivin expression in ovarian cancer is closely related to FIGO stage, tumor

| Study            | OR (95% CI) | Weight |
|------------------|-------------|--------|
| JU (2016)        | 0.10 (0.01, 0.94) | 10.10 |
| Huang (2011)     | 0.17 (0.02, 1.36) | 6.00  |
| Gao (2007)       | 0.19 (0.04, 0.87) | 11.59 |
| Liuang (2007)    | 0.32 (0.10, 1.02) | 15.82 |
| Yin (2008)       | 0.17 (0.03, 0.85) | 9.87  |
| Ma (2004)        | 0.22 (0.09, 0.50) | 27.83 |
| Zhang (2003)     | 0.26 (0.04, 1.59) | 6.79  |
| Sui (2002)       | 0.55 (0.17, 1.77) | 11.70 |
| Overall (I-squared = 0.0%, p = 0.8840) | 0.26 (0.16, 0.42) | 100.00 |

Fig 5. Tumor FIGO stage.
https://doi.org/10.1371/journal.pone.0194463.g005
grade. The differences of I—II compared with III—IV, G1-G2 compared with G3 were statistically significant (OR = 0.26, OR = 0.29 respectively, P < 0.00001). This suggest the later clinical stage, lower histological differentiation degree, the higher survivin positive expression. Survivin is correlated with the malignant degree of ovarian cancer. Altieri [36] found that survivin over expression was related to tumor metastasis. Zhou [37] found that survivin could promote the transfer of corpus cancer, but our study shows that survivin positive rate between lymph node metastasis and non-lymph metastasis was no statistically different (OR = 1.53, 95%CI (0.77,3.03, P = 0.23,P>0.05). This may be relevant to the different tumor types, or insufficiency of the number of research, or the various different experiment conditions, or the judgment of positive deviation. However, there were limitations to this meta-analysis. First, the techniques used to detect survivin may have differed between the included studies. We determined that IHC and RT-PCR are equally important for the detection of survivin. Second, the survivin antibodies used in the included studies do not discriminate survivin isoforms, so the results may reflect increases in total survivin levels. We suggest that these preliminary findings warrant further analyses in the future. Third, there is the possibility of publication bias, because small studies with null results tend not to be published, as well as outcome reporting biases. In conclusion, despite the above limitations, our meta-analysis supports that survivin overexpression is associated with FIGO stage and tumor grade of ovarian cancer. However, larger clinical studies must be performed to more thoroughly investigate the precise clinicopathological features associated with survivin.

| Study       | OR (95% CI)   | Weight |
|-------------|---------------|--------|
| Gao (2007)  | 0.07 (0.01, 0.39) | 25.29  |
| Liguang (2007) | 0.27 (0.09, 0.89) | 22.02  |
| Yin (2009)  | 0.10 (0.03, 0.31) | 14.34  |
| Ma (2004)   | 0.27 (0.07, 1.03) | 18.66  |
| Zhang (2003) | 1.11 (0.17, 7.22) | 4.25   |
| Su (2002)   | 0.89 (0.24, 3.09) | 10.40  |
| Overall (I-squared = 44.9%, p = 0.112) | 0.29 (0.17, 0.51) | 100.00 |

Fig 6. Tumor grade.

https://doi.org/10.1371/journal.pone.0194463.g006
Table 2. Sensitivity analyses.

| Groups                                 | Studies(n) | OR (95%CI) | heterogeneity test | P    | I²(%) |
|----------------------------------------|------------|------------|--------------------|------|-------|
| Ovarian cancer vs Ovarian benign tumor |            |            |                    |      |       |
| All studies                            | 11         | 9.86(5.13–18.95) | 0.004              | 61.2 |       |
| Omitting Kanter M[17]                  | 10         | 7.25(4.95–10.61) | 0.057              | 45.5 |       |
| Omitting Qian X[20]                    | 10         | 8.85(4.68–16.72) | 0.008              | 59.5 |       |
| Omitting Ma XY[25]                     | 10         | 11.36(5.60–23.07) | 0.010              | 58.5 |       |
| Omitting Kanter M[17],Qian X[20],Ma XY[25] | 8       | 7.66(4.88–12.02) | 0.161              | 33.4 |       |
| Ovarian cancer vs Borderline ovarian tumor |           |            |                    |      |       |
| All studies                            | 10         | 3.65(1.73–7.69) | 0.000              | 69.9 |       |
| Omitting Ju LL[16]                     | 9          | 4.46(2.18–9.10) | 0.004              | 65.1 |       |
| Omitting Kanter M[17]                  | 9          | 2.92(1.49–5.73) | 0.011              | 59.8 |       |
| Omitting Qian X[20]                    | 9          | 3.03(1.46–6.28) | 0.003              | 65.2 |       |
| Omitting Sui[11]                       | 9          | 4.27(1.98–9.21) | 0.003              | 66.3 |       |
| Omitting Ju LL[16], Kanter M[17],Qian X[20], and Sui[11] | 6          | 3.58(2.18–5.90) | 0.765              | 0.0  |       |

Fig 7. Lymphatic metastasis.

https://doi.org/10.1371/journal.pone.0194463.g007
Supporting information

S1 File. PRISMA 2009 checklist.doc and “PRISMA 2009 flow diagram.doc”.

Acknowledgments

KHY contributed to study concept and design; LY and HFW contributed to literature search, review of the studies, and data extractions; HLW and XHC contributed to data analysis and...
the study quality evaluation; XYH, SYM contributed to verify the statistical analysis and scrutinized data and supervision throughout the whole study. All the authors contributed writing the manuscript. All authors approved the final version of the manuscript.

**Author Contributions**

**Conceptualization:** Kehu Yang.

**Data curation:** Hailin Wang, Xiaohong Chen, Huifang Wu, Liang Yao.

**Formal analysis:** Xiaoyan He, Shouye Ma.

**Methodology:** Kehu Yang.

**Supervision:** Xiaoyan He, Shouye Ma.

**Writing – original draft:** Xiaoyan He, Hailin Wang, Xiaohong Chen, Huifang Wu, Liang Yao, Shouye Ma.

**Writing – review & editing:** Kehu Yang.

**References**

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009; 59(4):225–49. Epub 2009/05/29. https://doi.org/10.3322/caac.20006 PMID: 19474385.

2. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000; 89(10):2068–75. Epub 2000/11/07. PMID: 11066047.

3. FIGO (International Federation of Gynecology and Obstetrics) annual report on the results of treatment in gynecological cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynecology and Obstetrics. 2003; 83 Suppl 1:ix–xxii, 1–229. Epub 2004/02/07. PMID: 14763164.

4. Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikee S, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer research. 2007; 27(4c):2803–8. Epub 2007/08/19. PMID: 17695451.

5. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Yeap BY, Sugarbaker DJ, et al. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. The Journal of pathology. 2007; 211(4):439–46. Epub 2007/01/27. https://doi.org/10.1002/path.2120 PMID: 17253597.

6. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer research. 1998; 58(22):5071–4. Epub 1998/11/21. PMID: 9823313.

7. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000; 46(5):645–50. Epub 2000/04/15. https://doi.org/10.1136/gut.46.5.645 PMID: 10764707; PubMed Central PMCID: PMCPMC1727921.

8. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(1):127–34. Epub 2000/02/03. PMID: 10656440.

9. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(7):2100–4. Epub 1999/11/24. https://doi.org/10.1200/jco.1999.17.7.2100 PMID: 10561264.

10. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. International journal of molecular medicine. 2002; 10(2):211–6. Epub 2002/07/18. PMID: 12119561.

11. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. International journal of oncology. 2002; 21(2):315–20. Epub 2002/07/16. PMID: 12118327.

12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010; 25(9):603–5. Epub 2010/07/24. https://doi.org/10.1007/s10654-010-9491-z PMID: 20652370.
13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002; 21(11):1539–58. Epub 2002/07/12. https://doi.org/10.1002/sim.1186 PMID: 12111919.

14. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technical Bulletin. 1999; 8(41):752–9.

15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997; 315(7109):629–34. Epub 1997/10/06. PMID: 9310563; PubMed Central PMCID: PMC2127453.

16. Ju LL, Zhao CY, Ye KF, Yang H, Zhang J. Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. European review for medical and pharmacological sciences. 2016; 20(10):1933–58. Epub 2016/06/02. PMID: 27249597.

17. Kanter M, Turan G, Usta C, Usta A, Eisen HH, Tavli L, et al. Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms. Journal of molecular histology. 2016; 47(2):145–52. Epub 2016/01/28. https://doi.org/10.1007/s10735-016-9661-8 PMID: 26815661.

18. Plewka D, Jakubiec-Bartnik B, Morek M, Bogunia E, Bienioszek M, Wolski H, et al. Survivin in ovary tumors. Ginekologia polska. 2015; 86(7):525–30. Epub 2015/09/18. PMID: 26376531.

19. Turan G, Usta CS, Usta A, Kanter M, Tavli L, Karacan M, et al. The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables. Journal of molecular histology. 2014; 45(6):679–87. Epub 2014/08/12. https://doi.org/10.1007/s10735-014-9591-2 PMID: 25106503.

20. Qian X, Xi X, Li L. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Applied immunohistochemistry & molecular morphology: AIMM. 2011; 19(2):126–32. Epub 2010/08/21. https://doi.org/10.1097/PAI.0b013e3181e30dcd PMID: 20724919.

21. Huang Y, Jin H, Liu Y, Zhou J, Ding J, Cheng KW, et al. FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocrine-related cancer. 2011; 18(1):13–26. Epub 2010/10/15. https://doi.org/10.1677/ERC-09-0308 PMID: 20943720.

22. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cellular and molecular life sciences: CMLS. 2002; 59(8):1406–12. Epub 2002/10/15. PMID: 12363043.

23. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer research. 1998; 58(9):1808–12. Epub 1998/05/15. PMID: 9581817.

24. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PloS one. 2012; 7(3):e34100. Epub 2012/03/03. https://doi.org/10.1371/journal.pone.0034100 PMID: 22457815; PubMed Central PMCID: PMC3311582.

25. Li C, Li Z, Zhu M, Zhao T, Chen L, Ji W, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer letters. 2001; 163(1):109–16. Epub 2001/02/13. PMID: 11163114.

26. Okada E, Murali Y, Matsui K, Isizawa S, Cheng C, Masuda M, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer letters. 2001; 163(1):109–16. Epub 2001/02/13. PMID: 11163114.

27. Li C, Li Z, Zhu M, Zhao T, Chen L, Ji W, et al. Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis. PloS one. 2012; 7(9):e44764. Epub 2012/10/03. https://doi.org/10.1371/journal.pone.0044764 PMID: 23028610; PubMed Central PMCID: PMC3459962.

28. Liu HO, Wang YH, Wang LL, Hao M. P16INK4A and survivin: Diagnostic and prognostic markers in cervical intraepithelial neoplasia and cervical squamous cell carcinoma. Experimental and molecular...
33. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Current opinion in cell biology. 2006; 18(6):609–15. Epub 2006/08/29. https://doi.org/10.1016/jceb.2006.08.015 PMID: 16934447.

34. Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. International review of cytology. 2005; 247:35–88. Epub 2005/12/14. https://doi.org/10.1016/S0074-7696(05)47002-3 PMID: 16344111.

35. Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L, et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. British journal of cancer. 2005; 92(2):271–7. Epub 2005/01/19. https://doi.org/10.1038/sjbjc.6602332 PMID: 15655541; PubMed Central PMCID: PMCPMC2361852.

36. Altieri DC. Validating survivin as a cancer therapeutic target. Nature reviews Cancer. 2003; 3(1):46–54. Epub 2003/01/02. https://doi.org/10.1038/nrc968 PMID: 12509766.

37. Zhou XL, Wang M. Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis. Genetics and molecular research: GMR. 2015; 14(4):17059–67. Epub 2015/12/19. https://doi.org/10.4238/2015.December.16.6 PMID: 26681053.